Navigation Links
Polaris Group Files New IND for ADI-PEG 20 in Leukemia
Date:12/2/2013

SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug Administration (FDA) to begin Phase 1 clinical trials to test ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of acute myeloid leukemia. The FDA has reviewed this application, waived the 30-day review period and allowed treatment to begin. Polaris Group has previously filed other INDs under which it is conducting clinical trials on ADI-PEG 20 for the treatment of multiple other indications, including metastatic melanoma, prostate cancer, and hepatocellular carcinoma. The latter indication is already in a global Phase 3 study.

"This is another IND that expands the portfolio of indications for which ADI-PEG 20 is under development to hematologic malignancies," said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris Group. "Studies in leukemia and lymphoma will expand the studies currently underway with ADI-PEG 20, in addition to the solid tumors already under study. ADI-PEG 20 has a novel mechanism of action and well documented tolerability that we believe makes ADI-PEG 20 an ideal candidate both as monotherapy and to combine with other agents, including cytotoxics."

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to d
'/>"/>

SOURCE Polaris Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
2. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
3. Millennium HealthCare Inc. Installs VasoScan Cardiovascular Assessment Test in Select Physician Groups during First Week of Launch
4. The Huntzinger Management Group, Inc. (HMG) Reporting Significant Growth and Business Expansion in 2013
5. Jean Coutu Group chooses Microsoft Dynamics for Retail to streamline operations
6. Life Care Solutions Group: The #Vaginal Mesh Debacle Is More Complicated Then The Hip Settlement
7. Implantable Medical Device Group formed to Reduce Risk and Simplify Management of Active Implant Projects
8. Simcere Pharmaceutical Group Announces Extraordinary General Meeting of Shareholders
9. HyGreen, Inc. Signs Distribution Agreement with Unison Group
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
11. Triangle Insights Group Opens RTP Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
(Date:12/22/2014)... , Dec. 22, 2014 NxStage Medical, ... of innovative dialysis products, announced today that the ... its System One™ to perform hemodialysis overnight while ... home nocturnal hemodialysis. NxStage,s® System One is the ... FDA for this indication. Home ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... Aug. 4 Tolerx, Inc. , a ... and cancer by modulating T cell activity, today announced ... Ph.D., as Chief Scientific Officer. Dr. de Fougerolles’ appointment ... research and early-stage product development programs involving novel therapies ...
... Healthcare, Inc. (Nasdaq: GRMH ) will host a conference ... , to discuss the company,s financial results for Q2, 2010. Management will review ... , , , ... be webcast on the investor relations section of Graymark,s website at http://www.graymarkhealthcare.com ...
Cached Medicine Technology:Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 2Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 3Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 4Graymark Healthcare, Inc. to Host Conference Call to Discuss Q2 Financial Results 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... are encouraged to learn about Heart Failure-how to prevent it ... Failure Awareness Week February 8-14, 2009 Heart Failure Society ... Education Modules Available at www.abouthf.org ... is set for February 8-14. This is a ...
... Senior Market Sales, Inc., a leading independent marketing ... California, Inc., dba CalSurance, to offer Errors & Omissions ... open enrollment period launched Feb. 2, 2009. Insurance agents ... enroll for an 18-month policy effective March 1, 2009 ...
... all are sure that adolescents, use of cannabis causes cells ... marijuana over an extended period of time appears to greatly ... form of testicular cancer, a new study reveals. , In ... week or began to use the substance on a long-term ...
... with the holiday from fruit and wine to massage can ... The sweet delights of Valentine,s Day are thought of ... good for your heart, says a University of Michigan ... and wine, but there are components in tart cherries, grapes ...
... Medical,International Limited (NYSE: MR ), a ... today announced that it will report its,financial results ... December 31,2008, after the U.S. market closes on ... conference call at 8:00 AM on March 5, ...
... generate follow-up TRI compoundsWILMINGTON, Del., Feb. 9 ... Inc. today announced that AstraZeneca has licensed a ... for depression. Researchers at Virginia Tech ... The agreement provides AstraZeneca with a global license ...
Cached Medicine News:Health News:National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure 2Health News:National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure 3Health News:Senior Market Sales Offers Discounted E&O Insurance for Agents 2Health News:Senior Market Sales Offers Discounted E&O Insurance for Agents 3Health News:Marijuana Linked to Aggressive Testicular Cancer 2Health News:Marijuana Linked to Aggressive Testicular Cancer 3Health News:Marijuana Linked to Aggressive Testicular Cancer 4Health News:Valentine's Day Indulgences Can Be Heart Healthy 2Health News:Valentine's Day Indulgences Can Be Heart Healthy 3Health News:Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009 2Health News:AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration 2Health News:AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration 3Health News:AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration 4
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
... and high power negative lens delivering magnification ... benefit of this system is ease of ... made possible due to a superior depth ... and individual interpupillary adjustment provides stability for ...
... Left. 23 gauge thin wall ... Angled 20 degree shaft 10 mm ... set 0.5 mm behind aspiration tip. ... 46 cm (18.1 inches) of silicone ...
... pneumatic stools come with five legs for ... to 25" (total vertical travel 6"). 2" ... durable and fire retardant upholstery, available in ... by special order. Top of the range ...
Medicine Products: